ViaCyte Overview
- Founded
- 1999

- Status
- Private
- Employees
- 95

- Latest Deal Type
- 2ndary - Private
- Investors
- 28
ViaCyte General Information
Description
Operator of a regenerative medicine company intended to discover, develop and commercialize novel cell replacement therapies to treat human diseases. The company's therapies are based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device, enabling healthcare institutions to reduce diabetes-related complications efficiently.
Contact Information
- 3550 General Atomics Court
- San Diego, CA 92121
- United States
ViaCyte Timeline
ViaCyte Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
24. Secondary Transaction - Private | 00000 | Completed | Clinical Trials - General | |||
23. Later Stage VC (Series D) | 26-May-2020 | 0000 | 00000 | 00000 | Completed | Clinical Trials - General |
22. Corporate | 25-Sep-2018 | 0000 | 00000 | Completed | Clinical Trials - General | |
21. Grant | 17-Apr-2018 | 00.00 | 00000 | Completed | Clinical Trials - General | |
20. Grant | 15-Dec-2017 | 00.00 | 00000 | Completed | Clinical Trials - General | |
19. Later Stage VC | 22-May-2017 | 0000 | 00000 | Completed | Clinical Trials - General | |
18. Grant | 01-Jan-2017 | 000.00 | 00000 | Completed | Clinical Trials - General | |
17. Grant | 11-Sep-2014 | 000.00 | 00000 | Completed | Clinical Trials - General | |
16. Later Stage VC (Series C1) | 17-Jul-2013 | $16.5M | $104M | Completed | Clinical Trials - General | |
15. Grant | 26-Oct-2012 | $10.1M | $87.1M | Completed | Clinical Trials - General |
ViaCyte Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series D2 | 000,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
Series D1 | 000,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series D-IA | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series C1 | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
Series C | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
Series B | 27,876,992 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 3.93% |
Series A | 8,020,005 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 1.13% |
ViaCyte Comparisons
Industry
00000 00
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialViaCyte Competitors (30)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Semma Therapeutics | Formerly VC-backed | Cambridge, MA | 00000 | 000000&0 | 00000 | |
00000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 0000000000 | 00000 |
000000 000000000 | Formerly PE-Backed | Germantown, MD | 0 | 000.00 | 000000&0 | 000.00 |
000000000 | Formerly VC-backed | Tucson, AZ | 00 | 000.00 | 000000&0 | 000.00 |
0000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
ViaCyte Executive Team (15)
ViaCyte Board Members (14)
Name | Representing | Role | Since |
---|---|---|---|
Adam Koppel MD | Bain Capital | Board Member | 000 0000 |
Asish Xavier Ph.D | Self | Board Member | 000 0000 |
Fred Middleton | Sanderling Ventures | Board Member | 000 0000 |
Heath Lukatch Ph.D | TPG Biotech | Board Member | 000 0000 |
Ian Smith | Self | Executive Chairman | 000 0000 |
ViaCyte Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialViaCyte Investors (28)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Bain Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
RA Capital Management | Venture Capital | Minority | 000 0000 | 000000 0 | |
TPG Biotech | Venture Capital | Minority | 000 0000 | 000000 0 | |
CRISPR Therapeutics | Corporation | Minority | 000 0000 | 000000 0 | |
The National Institute of Diabetes and Digestive and Kidney Diseases | Government | 000 0000 | 000000 0 |
ViaCyte Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 (000000000 | 18-Dec-2015 | 000000000000000000 | Biotechnology | 0000 0000000 00.0 |